MAO is a possible Alzheimer's disease biomarker

December 7, 2016 | American Chemical Society

Researchers used mice studies to reveal that MAO activity (yellow) is directly correlated with the progression of Alzheimer's disease and may be used to stage the disease.
Credit: American Chemical Society

Alzheimer's disease affects more than 35 million people, a number that is expected to increase in the coming years.

Currently, Alzheimer's diagnoses rely on clinical neuropathologic assessment of amyloid-β (Aβ) peptide aggregates (plaques) and neurofibrillary tangles. But in ACS Central Science, researchers reveal that an enzyme already implicated in a host of neural disorders could someday serve as a biomarker.

See Also: Research discovers neuroprotective protein in blood is biomarker of Alzheimer's disease

In the brains of patients with Alzheimer's, amyloid peptides aggregate to form oligomers and plaques that are thought to be responsible for the disease symptoms.

It is difficult to monitor Aβ aggregation in living animals and patients, and current methods to track it in patient brains are costly, have low resolution or require radiation.

Monoamine oxidase (MAO) is involved in many neurological disorders, such as depression. In addition, MAO is known to be associated with Alzheimer's, but studies establishing this relationship were only conducted in lab dishes and test tubes.

Related: Imaging test may identify biomarker of Alzheimer's disease

To better understand MAO's association with Alzheimer's, and to determine whether MAO levels could be used as a biomarker for the disease, Inhee Mook-Jung, Kyo Han Ahn and colleagues took the next step and studied the protein in a mouse model of Alzheimer's.

The team devised an imaging tool to watch both Aβ and MAO at the same time in mice, and observed that as Aβ plaques increase (that is, as Alzheimer's progresses), MAO activity also increases.

The team also showed that there are three distinct phases of MAO activity that change along with Alzheimer's progression: a slow initiation stage, a subsequent aggressive stage and finally a saturation stage.

Read Next: Alzheimer's disease: Early biomarker defined

The authors say these results suggest that MAO could be helpful as a biomarker to someday diagnose and monitor the disease in patients, possibly using body fluids.

Note: Material may have been edited for length and content. For further information, please contact the cited source.

American Chemical Society

Publication

Kim D et al. Close Correlation of Monoamine Oxidase Activity with Progress of Alzheimer’s Disease in Mice, Observed by in Vivo Two-Photon Imaging.   ACS Central Science, Published Online December 7 2016. doi: 10.1021/acscentsci.6b00309

Comments